journal
https://read.qxmd.com/read/39356984/association-of-participation-in-medicare-s-oncology-care-model-with-spending-utilization-and-quality-outcomes-among-commercially-insured-and-medicare-advantage-members
#1
JOURNAL ARTICLE
Samyukta Mullangi, Benjamin Ukert, Andrea Devries, David Debono, Jason Santos, Michael J Fisch, Stephen M Schleicher, Amol S Navathe, Justin E Bekelman, Aaron L Schwartz, Ravi B Parikh
PURPOSE: The Oncology Care Model (OCM), a value-based payment model for traditional Medicare beneficiaries with cancer, yielded total spending reductions that were outweighed by incentive payments, resulting in net losses to the Centers for Medicare & Medicaid Services. We studied whether the OCM yielded spillover effects in total episode spending, utilization, and quality among commercially insured and Medicare Advantage (MA) members, who were not targeted by the program. PATIENTS AND METHODS: This observational study used administrative claims from a large national payer, yielding 157,189 total patients with commercial insurance or MA with solid malignancies who initiated 229,376 systemic anticancer therapy episodes before (2012-2015) and during (2016-2021) the OCM at 125 OCM-participating practices (a subset of total OCM practices) and a 1:10 propensity-matched set of 860 non-OCM practices...
October 2, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39356983/cancer-immunotherapy-trials-network-12-pembrolizumab-in-hiv-associated-kaposi-sarcoma
#2
JOURNAL ARTICLE
Kathryn Lurain, Ramya Ramaswami, Irene Ekwede, Vanessa Eulo, Gaurav Goyal, Manoj Menon, Thomas A Odeny, Elad Sharon, Michael J Wagner, Chia-Ching Jackie Wang, Nina Bhardwaj, Philip A Friedlander, Maher Abdul-Hay, Elena M Cornejo Castro, Nazzarena Labo, Vickie Ann Marshall, Wendell Miley, Kyle Moore, Romin Roshan, Denise Whitby, Angela Shaulov Kask, Judith Kaiser, Emma Han, Anna Wright, Robert Yarchoan, Steven P Fling, Thomas S Uldrick
PURPOSE: Cancer Immunotherapy Trials Network 12 demonstrated safety of pembrolizumab in treating advanced cancer in people with HIV. Here, we report results of the Kaposi sarcoma (KS) cohort. METHODS: In this multicenter phase I trial, we enrolled participants with HIV-associated KS on antiretroviral therapy with CD4+ ≥50 cells/μL and HIV plasma RNA <200 copies/mL. Pembrolizumab 200 mg intravenously was administered once every 3 weeks for up to 35 cycles...
October 2, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39356982/long-term-risk-of-subsequent-neoplasms-in-5-year-survivors-of-childhood-neuroblastoma-a-dutch-childhood-cancer-survivor-study-later-3-study
#3
JOURNAL ARTICLE
Aimée S R Westerveld, Godelieve A M Tytgat, Hanneke M van Santen, Max M van Noesel, Jacqueline Loonen, Andrica C H de Vries, Marloes Louwerens, Maria M W Koopman, Margriet van der Heiden-van der Loo, Geert O Janssens, Ronald R de Krijger, Cecile M Ronckers, Helena J H van der Pal, Leontien C M Kremer, Jop C Teepen
PURPOSE: Neuroblastoma survivors have an increased risk of developing subsequent malignant neoplasms (SMNs), but the risk of subsequent nonmalignant neoplasms (SNMNs) and risk factors are largely unknown. We analyzed the long-term risks and associated risk factors for developing SMNs and SNMNs in a well-characterized cohort of 5-year neuroblastoma survivors. METHODS: We included 563 5-year neuroblastoma survivors from the Dutch Childhood Cancer Survivor Study (DCCSS)-LATER cohort, diagnosed during 1963-2014...
October 2, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39356980/phase-ib-study-for-the-combination-of-doxorubicin-dacarbazine-and-nivolumab-as-the-upfront-treatment-in-patients-with-advanced-leiomyosarcoma-a-study-by-the-spanish-sarcoma-group-geis
#4
JOURNAL ARTICLE
Javier Martin-Broto, Roberto Diaz-Beveridge, David Moura, Rafael Ramos, Javier Martinez-Trufero, Irene Carrasco, Ana Sebio, Enrique González-Billalabeitia, Antonio Gutierrez, Javier Fernandez-Jara, Laura Hernández-Vargas, Josefina Cruz, Claudia Valverde, Nadia Hindi
PURPOSE: Doxorubicin, alongside a select group of cytotoxic agents, is capable of inducing an adaptive immune response via a well-established peculiar type of tumor cell death called immunogenic cell death (ICD). We hypothesize that combining doxorubicin and dacarbazine with nivolumab may enhance therapeutic efficacy by exerting synergy in the ICD circuit. We hereby present a phase Ib trial with this combination. PATIENTS AND METHODS: Patients with advanced leiomyosarcoma and anthracycline-naïve were eligible...
October 2, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39356979/delivering-high-quality-cancer-care-charting-a-new-course-for-a-system-in-crisis-one-decade-later
#5
JOURNAL ARTICLE
Larissa Nekhlyudov, Laura A Levit, Patricia A Ganz
In 2012, the National Academies of Sciences, Engineering, and Medicine convened a committee charged with addressing the quality of cancer care in the United States and providing recommendations to policymakers and the cancer care community on strategies to improve cancer care delivery from the time of diagnosis through end-of-life. The resulting committee report, titled Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis (2013), presented a conceptual framework that included six interconnected components of care with corresponding recommendations...
October 2, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39356978/hormonal-contraception-and-breast-cancer-risk-for-carriers-of-germline-mutations-in-brca1-and-brca2
#6
JOURNAL ARTICLE
Kelly-Anne Phillips, Joanne Kotsopoulos, Susan M Domchek, Mary Beth Terry, James A Chamberlain, Julie K Bassett, Amber M Aeilts, Irene L Andrulis, Saundra S Buys, Wanda Cui, Mary B Daly, Andrea F Eisen, William D Foulkes, Michael L Friedlander, Jacek Gronwald, John L Hopper, Esther M John, Beth Y Karlan, Raymond H Kim, Allison W Kurian, Jan Lubinski, Kelly Metcalfe, Katherine L Nathanson, Christian F Singer, Melissa C Southey, Heather Symecko, Nadine Tung, Steven A Narod, Roger L Milne
PURPOSE: It is uncertain whether, and to what extent, hormonal contraceptives increase breast cancer (BC) risk for germline BRCA1 or BRCA2 mutation carriers. METHODS: Using pooled observational data from four prospective cohort studies, associations between hormonal contraceptive use and BC risk for unaffected female BRCA1 and BRCA2 mutation carriers were assessed using Cox regression. RESULTS: Of 3,882 BRCA1 and 1,509 BRCA2 mutation carriers, 53% and 71%, respectively, had ever used hormonal contraceptives for at least 1 year (median cumulative duration of use, 4...
October 2, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39356977/role-for-artificial-intelligence-in-the-detection-of-immune-related-adverse-events
#7
EDITORIAL
Mohamed I Elsaid, Alexa Simon Meara, Dwight H Owen
No abstract text is available yet for this article.
October 2, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39356975/survival-outcomes-associated-with-first-line-procarbazine-ccnu-and-vincristine-or-temozolomide-in-combination-with-radiotherapy-in-idh-mutant-1p-19q-codeleted-grade-3-oligodendroglioma
#8
JOURNAL ARTICLE
Salah Eddine O Kacimi, Caroline Dehais, Loïc Feuvret, Olivier Chinot, Catherine Carpentier, Charlotte Bronnimann, Elodie Vauleon, Apolline Djelad, Elizabeth Cohen-Jonathan Moyal, Olivier Langlois, Mario Campone, Mathilde Ducloie, Georges Noel, Stefania Cuzzubbo, Luc Taillandier, Carole Ramirez, Nadia Younan, Philippe Menei, Frédéric Dhermain, Christine Desenclos, François Ghiringhelli, Veronique Bourg, Damien Ricard, Thierry Faillot, Romain Appay, Emeline Tabouret, Lucia Nichelli, Bertrand Mathon, Alice Thomas, Suzanne Tran, Franck Bielle, Agusti Alentorn, J Bryan Iorgulescu, Pierre-Yves Boëlle, Karim Labreche, Khê Hoang-Xuan, Marc Sanson, Ahmed Idbaih, Dominique Figarella-Branger, François Ducray, Mehdi Touat
PURPOSE: Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3IDHmt/Codel ) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemotherapy regimen between procarbazine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine (PCV) and temozolomide (TMZ) remains unclear given the lack of randomized trial data comparing both regimens. METHODS: The objective was to assess the overall survival (OS) and progression-free survival (PFS) associated with first-line PCV/RT versus TMZ/RT in patients newly diagnosed with O3IDHmt/Codel ...
October 2, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39353167/will-prolyl-hydroxylase-inhibitors-supplant-erythropoiesis-stimulating-agents-and-iv-iron-in-the-treatment-of-chemotherapy-induced-anemia
#9
EDITORIAL
George M Rodgers, Jeffrey A Gilreath
No abstract text is available yet for this article.
October 1, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39353166/minimally-invasive-assessment-of-peripheral-residual-disease-during-maintenance-or-observation-in-transplant-eligible-patients-with-multiple-myeloma
#10
JOURNAL ARTICLE
Marta Lasa, Laura Notarfranchi, Cristina Agullo, Carmen Gonzalez, Sergio Castro, Jose J Perez, Leire Burgos, Camila Guerrero, Maria Jose Calasanz, Juan Flores-Montero, Albert Oriol, Joan Bargay, Rafael Rios, Valentin Cabañas, Carmen Cabrera, Rafael Martinez-Martinez, Cristina Encinas, Felipe De Arriba, Miguel-Teodoro Hernandez, Luis Palomera, Alberto Orfao, Joaquin Martinez-Lopez, Maria-Victoria Mateos, Jesus San-Miguel, Juan Jose Lahuerta, Laura Rosiñol, Joan Blade, Maria Teresa Cedena, Noemi Puig, Bruno Paiva
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. In multiple myeloma (MM), measurable residual disease (MRD) is assessed in bone marrow (BM)...
October 1, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39353165/can-we-find-a-place-for-trophoblast-cell-surface-antigen-2-targeted-antibody-drug-conjugates-in-lung-cancer
#11
EDITORIAL
Alissa J Cooper, Gregory J Riely
No abstract text is available yet for this article.
October 1, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39353164/sexual-health-and-quality-of-life-in-patients-with-low-risk-early-stage-cervical-cancer-results-from-gcig-cctg-cx-5-shape-trial-comparing-simple-versus-radical-hysterectomy
#12
JOURNAL ARTICLE
Sarah E Ferguson, Lori A Brotto, Janice Kwon, Vanessa Samouelian, Gwenael Ferron, Amandine Maulard, Cor de Kroon, Willemien Van Driel, John Tidy, Karin Williamson, Sven Mahner, Stefan Kommoss, Frederic Goffin, Karl Tamussino, Brynhildur Eyjolfsdottir, Jae-Weon Kim, Noreen Gleeson, Dongsheng Tu, Lois Shepherd, Marie Plante
PURPOSE: Simple hysterectomy and pelvic node assessment (SHAPE) is a phase III randomized trial (ClinicalTrials.gov identifier: NCT01658930) reporting noninferiority of simple compared with radical hysterectomy for oncologic outcomes in low-risk cervical cancer. This study presents secondary outcomes of sexual health and quality of life (QOL) of the SHAPE trial. METHODS: Participants were randomly assigned to receive either radical or simple hysterectomy. Sexual health was assessed up to 36 months postoperatively using the Female Sexual Function Index (FSFI) and Female Sexual Distress Scale-Revised and QOL using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and Cervical Cancer-Specific Module (QLQ-CX24) questionnaires...
October 1, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39353163/efficacy-and-safety-of-roxadustat-for-anemia-in-patients-receiving-chemotherapy-for-nonmyeloid-malignancies-a-randomized-open-label-active-controlled-phase-iii-study
#13
JOURNAL ARTICLE
Shun Lu, Jiong Wu, Jin Jiang, Qisen Guo, Yan Yu, Yu Liu, Hua Zhang, Ling Qian, Xiumei Dai, Yanyan Xie, Ting Fu, Tyson Lee, Yan Lu, Rui Ma, Mark D Eisner
PURPOSE: We evaluated the efficacy and safety of roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor, for chemotherapy-induced anemia (CIA) in patients with nonmyeloid malignancies receiving multicycle treatments of chemotherapy. PATIENTS AND METHODS: In this open-label, noninferiority phase III study conducted at 44 sites in China, 159 participants age ≥18 years with CIA nonmyeloid malignancy and CIA were randomly assigned (1:1) to oral roxadustat or subcutaneous recombinant human erythropoietin-α (rHuEPO-α) three times a week for 12 weeks...
October 1, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39353162/on-the-nose-reducing-nasopharyngeal-cancer-related-mortality-using-risk-based-epstein-barr-virus-serology-screening
#14
EDITORIAL
Philip E Castle, Paul K J Han
No abstract text is available yet for this article.
October 1, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39353161/battle-of-the-sexes-in-the-clonal-world
#15
EDITORIAL
Theodoros Karantanos, Tania Jain
No abstract text is available yet for this article.
October 1, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39353160/impact-of-an-epstein-barr-virus-serology-based-screening-program-on-nasopharyngeal-carcinoma-mortality-a-cluster-randomized-controlled-trial
#16
JOURNAL ARTICLE
Wen-Jie Chen, Xia Yu, Yu-Qiang Lu, Ruth M Pfeiffer, Wei Ling, Shang-Hang Xie, Zhi-Cong Wu, Xue-Qi Li, Yu-Ying Fan, Biao-Hua Wu, Kuang-Rong Wei, Hui-Lan Rao, Qi-Hong Huang, Xiang Guo, Ying Sun, Jun Ma, Qing Liu, Allan Hildesheim, Ming-Huang Hong, Yi-Xin Zeng, Ming-Fang Ji, Zhiwei Liu, Su-Mei Cao
PURPOSE: Screening for nasopharyngeal carcinoma (NPC) has shown an improvement in early detection and survival rates of NPC in endemic regions. It is critical to evaluate whether NPC screening can reduce NPC-specific mortality in the population. METHODS: Sixteen towns in Sihui and Zhongshan cities, China, were selected; eight were randomly allocated to the screening group and eight to the control group. Residents age 30-69 years with no history of NPC were included from January 1, 2008, to December 31, 2015...
October 1, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39348631/rain-talk
#17
JOURNAL ARTICLE
Karl A Lorenz
No abstract text is available yet for this article.
September 30, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39348625/circulating-tumor-dna-sequencing-for-biologic-classification-and-individualized-risk-stratification-in-patients-with-hodgkin-lymphoma
#18
JOURNAL ARTICLE
Jan-Michel Heger, Laman Mammadova, Julia Mattlener, Sophia Sobesky, Melita Cirillo, Janine Altmüller, Elisabeth Kirst, Sarah Reinke, Wolfram Klapper, Paul J Bröckelmann, Justin Ferdinandus, Helen Kaul, Gundolf Schneider, Jessica Schneider, Julia Katharina Schleifenbaum, Roland T Ullrich, Max Freihammer, Sabine Awerkiew, Mia Lohmann, Florian Klein, Peter Nürnberg, Michael Hallek, Davide Rossi, Christine Mauz-Körholz, Stefan Gattenlöhner, Andreas Bräuninger, Peter Borchmann, Bastian von Tresckow, Sven Borchmann
PURPOSE: Current clinical challenges in Hodgkin lymphoma (HL) include difficult-to-treat relapsed/refractory disease and considerable long-term toxicities of treatment. Since clinical risk factors lack discriminatory power, intensity of therapy is mainly based on tumor burden. Exploring HL genetics and tumor microenvironment (TME) might provide valuable insights for improved risk stratification. MATERIALS AND METHODS: In this study, we applied circulating tumor DNA sequencing to 243 patients obtained from pivotal German Hodgkin Study Group trials to identify subtypes of HL...
September 30, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39348624/the-effect-on-travel-distance-of-a-statewide-regionalization-policy-for-initial-breast-cancer-surgery
#19
JOURNAL ARTICLE
Nina A Bickell, Ann B Nattinger, Emily L McGinley, Maria J Schymura, Purushottam W Laud, Liliana E Pezzin
PURPOSE: Reimbursement strategies to regionalize care can be effective for improving patient outcomes but may adversely affect access to care. We sought to determine the effect on travel distance for surgical treatment of a 2009 New York State (NYS) policy restricting Medicaid reimbursement for breast cancer surgery at low-volume hospitals. PATIENTS AND METHODS: From a linked data set merging the NYS tumor registry with hospital discharge data, we identified women younger than 65 years with stage I-III first breast tumors from pre- and post-policy periods...
September 30, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/39348606/-tert-expression-and-clinical-outcome-in-pulmonary-carcinoids
#20
JOURNAL ARTICLE
Lisa Werr, Christoph Bartenhagen, Carolina Rosswog, Maria Cartolano, Catherine Voegele, Alexandra Sexton-Oates, Alex Di Genova, Angela Ernst, Yvonne Kahlert, Nadine Hemstedt, Stefanie Höppner, Audrey Mansuet Lupo, Giuseppe Pelosi, Luka Brcic, Mauro Papotti, Julie George, Graziella Bosco, Alexander Quaas, Laura H Tang, Kenneth Robzyk, Kyuichi Kadota, Mee Sook Roh, Rachel E Fanaroff, Christina J Falcon, Reinhard Büttner, Sylvie Lantuejoul, Natasha Rekhtman, Charles M Rudin, William D Travis, Nicolas Alcala, Lynnette Fernandez-Cuesta, Matthieu Foll, Martin Peifer, Roman K Thomas, Matthias Fischer
PURPOSE: The clinical course of pulmonary carcinoids ranges from indolent to fatal disease, suggesting that specific molecular alterations drive progression toward the fully malignant state. A similar spectrum of clinical phenotypes occurs in pediatric neuroblastoma, in which activation of telomerase reverse transcriptase ( TERT ) is decisive in determining the course of disease. We therefore investigated whether TERT expression defines the clinical fate of patients with pulmonary carcinoid...
September 30, 2024: Journal of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.